PORTLAND, Ore., May 2, 2016 /PRNewswire/ — AbSci announced today the appointment of V. Bryan Lawlis, Ph.D. to AbSci’s Board of Directors. Dr. Lawlis has been the CEO and founder of numerous biotechnology companies and currently serves on the Board of Directors of BioMarin Pharmaceutical, Inc., Coherus BioSciences, Inc., and Geron, Inc.
“Dr. Lawlis brings over 35 years of experience in the biotech industry, where he has been a successful CEO, entrepreneur, scientist, and pioneer in the fields of biopharmaceutical process development and manufacturing,” said Sean McClain, Founder and CEO of AbSci. “We are honored to welcome Dr. Lawlis to our Board of Directors and we look forward to his input and guidance as we commercialize AbSci’s SoluPro technology.”
“I am very excited about the opportunity to join AbSci’s Board of Directors,” said Dr. Lawlis. “AbSci’s unique SoluPro technology has great potential to enhance speed and efficiency of development of key proteins in our industry. I look forward to sharing with the company my years of experience in the development of technologies for manufacturing of therapeutic proteins, partnering SoluPro and commercialization of products manufactured by this approach.”
Previously, Dr. Lawlis co-founded and served as President and CEO of Itero Biopharmaceuticals, Inc. from 2006 to 2011. Prior to Itero, he was President and CEO of Aradigm Corporation from August 2004 and served on its Board of Directors from February 2005, continuing in both capacities until August 2006. Dr. Lawlis served as Aradigm Corporation’s President and COO from June 2003 to August 2004. Dr. Lawlis co-founded Covance Biotechnology Services, a contract biopharmaceutical manufacturing operation, and served as its President and CEO from 1996 to 1999, and Chairman from 1999 to 2001, when it was acquired by Diosynth, Inc., a division of Akzo Nobel, NV. From 1981 to 1996, Dr. Lawlis was employed at Genencor, Inc., and Genentech, Inc. His last position at Genentech, Inc. was Vice President of Process Sciences.
Dr. Lawlis is a board member of the following publicly traded companies: BioMarin Pharmaceutical, Inc., Coherus BioSciences, Inc., Geron, Inc. In addition, Dr. Lawlis serves on the boards of two private companies, Sutro Biopharma, Inc. and Reform Biologics, LLC.
Dr. Lawlis holds a B.A. in Microbiology from the University of Texas at Austin and a Ph.D. in Biochemistry from Washington State University.
AbSci is a global leader in protein production technologies. The company’s SoluPro™expression platform achieves revolutionary yields of soluble and active protein products. AbSci’s unique approach accelerates drug discovery timelines, increases manufacturing efficiencies, and drastically reduces costs for the biopharmaceutical industry. For more information, please visitwww.abscibio.com.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/absci-appoints-v-bryan-lawlis-phd-to-board-of-directors-300260515.html